Is finerenone indicated for heart failure with preserved ejection fraction (EF ≥ 50%) in patients with chronic kidney disease and type 2 diabetes on guideline‑directed therapy?

Finerenone for Heart Failure with Preserved Ejection Fraction

Finerenone is NOT currently indicated for HFpEF based solely on preserved ejection fraction, chronic kidney disease, and type 2 diabetes—the established indication requires the specific combination of CKD with albuminuria (UACR ≥30 mg/g) in patients with type 2 diabetes, regardless of heart failure status.

Current Evidence-Based Indications

For Diabetic Kidney Disease (Established)

Finerenone is strongly recommended for patients with type 2 diabetes and CKD who have:

• eGFR ≥25 mL/min/1.73 m²
• Albuminuria (UACR ≥30 mg/g)
• Maximum tolerated doses of ACE inhibitor or ARB
• Serum potassium ≤4.8 mmol/L (or ≤5.0 mmol/L per FDA label)

This recommendation is based on the FIDELIO-DKD and FIGARO-DKD trials, which demonstrated a 13-14% reduction in cardiovascular events (including heart failure hospitalizations) and 23-36% reduction in kidney disease progression 111. The pooled FIDELITY analysis (N=13,171) confirmed these benefits across the CKD spectrum, explicitly excluding patients with heart failure with reduced ejection fraction 11.

Dosing Algorithm

• eGFR >60 mL/min/1.73 m²: Start 20 mg once daily
• eGFR 25-60 mL/min/1.73 m²: Start 10 mg once daily
• Uptitrate to 20 mg after 1 month if potassium ≤4.8 mmol/L and eGFR stable 11

The HFpEF Question: Recent Evolution

FINEARTS-HF Trial Context

The most recent evidence from FINEARTS-HF (2024) evaluated finerenone specifically in heart failure with mildly reduced or preserved ejection fraction (LVEF ≥40%) 23. This trial showed reduced worsening heart failure events independent of CKD or type 2 diabetes status 3. However, this represents emerging evidence that has not yet been fully incorporated into major diabetes or CKD guidelines as of 2023.

Current Guideline Position (2023)

The 2023 ADA Standards of Care explicitly state that finerenone trials (FIGARO-DKD and FIDELIO-DKD) excluded patients with heart failure with reduced ejection fraction 111. The primary indication remains cardiovascular and renal protection in diabetic kidney disease with albuminuria, where heart failure hospitalization reduction was a secondary benefit, not the primary target.

Critical Clinical Algorithm

For your specific patient (HFpEF + CKD + T2D):

1. Check albuminuria status first

   • If UACR ≥30 mg/g → Finerenone IS indicated per current guidelines 45
   • If UACR <30 mg/g → Finerenone is NOT indicated per 2023 guidelines

2. Verify eGFR ≥25 mL/min/1.73 m² 11

3. Confirm potassium ≤5.0 mmol/L 5

4. Ensure maximum tolerated RAS inhibition (ACE-I or ARB) 45

5. Prioritize SGLT2 inhibitor first if not already prescribed

   • SGLT2 inhibitors have Class A recommendations for HFpEF regardless of diabetes/CKD status 4
   • They reduce hyperkalemia risk when combined with finerenone 2

Practical Considerations

Hyperkalemia Management

• Occurs in 10.8% vs 5.3% placebo, but only 1.2% discontinue 11
• Monitor potassium at 4 weeks after initiation/dose change 5
• Withhold if K+ >5.5 mmol/L; restart at 10 mg when K+ ≤5.0 mmol/L 5

Combination Therapy

The 2023 guidelines recommend considering combined SGLT2 inhibitor + GLP-1 RA for additive cardiovascular/kidney benefit 4. Finerenone adds a third mechanism (mineralocorticoid receptor antagonism) specifically when albuminuria persists despite these therapies 15.

Common Pitfall

Do not confuse the cardiovascular benefits seen in diabetic CKD trials (which included HF hospitalization reduction as a composite endpoint) with a specific HFpEF indication. The trials that established finerenone's approval specifically excluded HFrEF patients and required albuminuria as an entry criterion 111.

Bottom Line

If your patient has albuminuria (UACR ≥30 mg/g), finerenone is indicated per 2023 guidelines to reduce cardiovascular events and CKD progression 45. The fact that they have HFpEF makes this even more compelling given the heart failure hospitalization benefits demonstrated in FIGARO-DKD 11. However, without albuminuria, current guidelines do not support finerenone use, though emerging FINEARTS-HF data may change this in future guideline iterations 3.